Rivaroxaban Compares Favorably with Enoxaparin in Preventing Venous Thromboembolism


Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism (VTE) in hospitalized patients with acute medical illnesses.

In the study, rivaroxaban met its primary clinical efficacy objectives of demonstrating non-inferiority to enoxaparin in short-term use (10 ± 4 days), and superiority in long-term use (35 ± 4 days) when compared to short-term use of enoxaparin followed by placebo. The combined rates of major and clinically relevant non-major bleeding, the primary safety measure in the study, while low overall, were significantly higher in those treated with rivaroxaban compared with those treated with enoxaparin, followed by placebo. The results were presented today as a late-breaker at the American College of Cardiology Annual Scientific Session in New Orleans.

Read more…


All active news articles

Get Involved

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.